NCT05996848

A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight

Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-Weekly in Chinese Participants With Overweight or Obesity

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 300 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will look at how well the new medicine CagriSema helps people with excess body weight losing weight compared to a "dummy" medicine and a medicine called semaglutide. Participants will either get CagriSema, a dummy medicine or semaglutide. Which treatment participants get is decided by chance. Participants will take one injection once a week. The study medicine will be injected briefly with a thin needle, typically in the stomach, thighs or upper arms. The study will last for about 1 year.

Conditions

• Obesity or Overweight

Interventions

Type	Name	Description
DRUG	Cagrilintide	Participants will receive 2.4 mg cagrilintide subcutaneously.
DRUG	Semaglutide	Participants will receive 2.4 mg semaglutide subcutaneously.
DRUG	Placebo Semaglutide	Participants will receive placebo matched to semaglutide subcutaneously.
DRUG	Placebo Cagrilintide	Participants will receive placebo matched to cagrilintide subcutaneously.

Timeline

• Start date: 2023-08-15
• Primary completion: 2025-01-06
• Completion: 2025-02-22
• First posted: 2023-08-18
• Last updated: 2026-01-09

Locations

37 sites across 1 country: China

Regulatory

• FDA-regulated drug study